SGMO - RBC Capital downgrades Sangamo as biotech moves to save cash
2023-11-03 15:32:03 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript
- Sangamo Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction
- Sangamo Therapeutics GAAP EPS of -$0.59 misses by $0.26, revenue of $9.39M misses by $1.01M
- Sangamo Therapeutics Q3 2023 Earnings Preview
For further details see:
RBC Capital downgrades Sangamo as biotech moves to save cash